$48.68
3.14%
Nasdaq, Sep 12, 10:00 pm CET
ISIN
US6402681083
Symbol
NKTR

Nektar Therapeutics Stock price

$48.68
+25.08 106.27% 1M
+36.38 295.77% 6M
+34.73 248.96% YTD
+29.93 159.63% 1Y
-8.47 14.82% 3Y
-247.57 83.57% 5Y
-139.12 74.08% 10Y
-232.57 82.69% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
+1.48 3.14%
ISIN
US6402681083
Symbol
NKTR
Industry

Key metrics

Basic
Market capitalization
$925.8m
Enterprise Value
$749.9m
Net debt
positive
Cash
$175.9m
Shares outstanding
12.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.4 | 21.4
EV/Sales
10.0 | 17.3
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
20.0%
Return on Equity
-195.9%
ROCE
-102.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$74.9m | $43.3m
EBITDA
$-137.2m | $-143.8m
EBIT
$-139.1m | $-164.2m
Net Income
$-122.3m | $-150.0m
Free Cash Flow
$-186.1m
Growth (TTM | estimate)
Revenue
-19.5% | -56.0%
EBITDA
-6.6% | -14.6%
EBIT
-3.0% | -26.4%
Net Income
30.9% | -26.1%
Free Cash Flow
-6.1%
Margin (TTM | estimate)
Gross
83.4%
EBITDA
-183.1% | -331.9%
EBIT
-185.7%
Net
-163.2% | -346.1%
Free Cash Flow
-248.3%
More
EPS
$-8.7
FCF per Share
$-14.9
Short interest
6.0%
Employees
61
Rev per Employee
$1.6m
Show more

Is Nektar Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.

Nektar Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

11x Buy
79%
2x Hold
14%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Nektar Therapeutics forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Nektar Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
75 75
20% 20%
100%
- Direct Costs 12 12
67% 67%
17%
63 63
13% 13%
83%
- Selling and Administrative Expenses 78 78
2% 2%
103%
- Research and Development Expense 124 124
12% 12%
166%
-137 -137
7% 7%
-183%
- Depreciation and Amortization 1.97 1.97
69% 69%
3%
EBIT (Operating Income) EBIT -139 -139
3% 3%
-186%
Net Profit -122 -122
31% 31%
-163%

In millions USD.

Don't miss a Thing! We will send you all news about Nektar Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nektar Therapeutics Stock News

Neutral
PRNewsWire
6 days ago
SAN FRANCISCO , Sept. 9, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will present results from the ongoing REZOLVE-AD Phase 2b study at the 2025 European Academy of Dermatology and Venereology (EADV) Congress being held in Paris, France from September 17-20, 2025.
Positive
The Motley Fool
10 days ago
Nektar Therapeutics (NKTR 7.73%) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program.
Neutral
PRNewsWire
11 days ago
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C.
More Nektar Therapeutics News

Company Profile

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.

Head office United States
CEO Howard Robin
Employees 61
Founded 1990
Website www.nektar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today